Clinical Trials
62 trialsMetronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial
Zhejiang Cancer Hospital
RC48-ADC in HER2-low Advanced Breast Cancer
RenJi Hospital
Emulation of the PALOMA-2 Trial
Brigham and Women's Hospital
Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
Emulation of the MONALEESA-2 Trial Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
ADELA
MedSIR
PONTIAC
MedSIR
Rehabilitation for People With Advanced Cancer
University Health Network, Toronto
Acceptability and Feasibility of PSC Model of Serious Illness Communication
National Cancer Centre, Singapore
Dalpiciclib in HR+/HER2- ABC
RenJi Hospital
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
WIN-B
MedSIR
OASIS
UNICANCER
ESPERO
Seoul National University Hospital
CORIN-PYRA
RenJi Hospital
ITHRAN
RenJi Hospital
Trastuzumab Deruxtecan in Advanced Breast Cancer
RenJi Hospital
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
RenJi Hospital
HERMIONE-7
University of Milano Bicocca
HERMIONE-13
University of Milano Bicocca
Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer
Fudan University
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Post-CDK
Seoul National University Hospital
CAMELIA
The First Affiliated Hospital with Nanjing Medical University
A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer
Affiliated Cancer Hospital of Shantou University Medical College
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer
Fudan University
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
The First Affiliated Hospital with Nanjing Medical University
COMETABreast
Spanish Breast Cancer Research Group
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Beijing GoBroad Hospital
A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer
Duke University
PERGIQUAL
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
The First Affiliated Hospital with Nanjing Medical University
CYSTATINcDK4/6
Erasmus Medical Center
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)
Peking Union Medical College Hospital
Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects
Ahon Pharmaceutical Co., Ltd.
CAILA
MedSIR
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
Abramson Cancer Center at Penn Medicine
VEX
European Institute of Oncology
EDALINE
Spanish Breast Cancer Research Group
PANGEA
Spanish Breast Cancer Research Group
POLTER
MedSIR
OPHELIA
MedSIR
KATIA
Spanish Breast Cancer Research Group
Dalpiciclib Plus Letrozole and Capecitabine
Fujian Medical University Union Hospital
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
Ahon Pharmaceutical Co., Ltd.